Vasheghani, 508 patient vitamin D prophylaxis study: 30% lower mortality [p=0.45] and 64% lower ICU admission [p=0.009] https://c19p.org/vasheghani
copied to clipboard
The relationship between serum 25-hydroxyvitamin D levels and the severity of COVID-19 disease and its mortality
et al., Scientific Reports, doi:10.1038/s41598-021-97017-9 (preprint 1/18/2021) (Preprint)
Retrospective 508 hospitalized COVID-19 patients in Iran showing lower mortality with vitamin D supplementation (not reaching statistical significance), and an association between lower vitamin D levels and disease severity, ICU admission, and increased mortality. Details of supplementation are not provided. The multivariate result for vitamin D deficiency is in the preprint, the journal version only contains the multivariate result for serum level.
|
risk of death, 30.4% lower, RR 0.70, p = 0.45, treatment 7 of 88 (8.0%), control 48 of 420 (11.4%), NNT 29, vitamin D supplementation.
|
|
risk of ICU admission, 63.8% lower, RR 0.36, p = 0.009, treatment 13 of 185 (7.0%), control 53 of 323 (16.4%), NNT 11, adjusted per study, vitamin D levels >30ng/mL.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Vasheghani et al., 1/18/2021, retrospective, Iran, Middle East, preprint, 6 authors, dosage not specified.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.